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Many conceptual advances in biology have been achieved by experimen-
tal studies using planar two-dimensional 
cell culture systems. Recent adaptations 
of molecular techniques to three-dimen-
sional model systems are bridging the 
gap in our understanding of biological 
events in vitro and in vivo in the study 
of disease progression. Recently, in vitro 
studies using Förster resonance energy 
transfer (FRET) have shown that the 
prototypical RhoGTPases Cdc42, Rac 
and RhoA are temporally and spatially 
synchronized during cell migration, with 
initial RhoA activity inducing protrusion 
prior to activation of Rac. This simulta-
neous FRET approach illustrates the 
tight control and dynamic regulation of 
RhoGTPase activity necessary for coor-
dinated cell migration in vitro. Here, 
we discuss our recent work using FLIM-
FRET analysis in a three-dimensional 
setting to reveal another layer of regula-
tion in which RhoA activity is governed 
by the extracellular microenvironment. 
We demonstrate that RhoA is spatially 
regulated into discrete fractions of activ-
ity at the leading edge and rear of cells 
during invasion in vivo or within three-
dimensional matrices. Significantly, this 
spatial regulation of RhoA was absent in 
two-dimensional in vitro settings. This 
distinct sub-cellular regulation of RhoA 
at the poles of invading cells in three-
dimensions sets a precedent that other 
RhoGTPases or signaling proteins may 
also be differentially regulated in a con-
text-dependent manner during key bio-
logical processes such as invasion.
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Introduction
In the past 15 years, the application 
of Förster resonance energy transfer 
(FRET) for the in vitro study of molecu-
lar dynamics has considerably improved 
our understanding of spatially restricted 
and temporally regulated protein-protein 
interactions underlying the etiology of 
many diseases. FRET is a non-radiative 
process involving the transfer of energy 
from an excited donor fluorophore to 
a second acceptor fluorophore that lie 
within close proximity (~10 nm) of each 
other. Using fluorescently tagged proteins, 
FRET has allowed the sub-cellular analy-
sis of ‘when and where’ protein interac-
tions may occur in live cells.
A frequent method used to measure 
FRET during protein-protein interac-
tions is referred to as ratiometric FRET, 
where the ratio of both fluorescently 
tagged protein intensities is analyzed in a 
pixel by pixel manner over the course of 
the experiment. In this way, the activation 
and interaction of a number of key signal-
ing proteins have been assessed at sub-
cellular resolution in vitro.1 A key caveat 
to this technique is the requirement that 
similar and constant levels of each fluo-
rophore must be present throughout the 
course of the experiment.2 To circumvent 
this, many experiments use single ‘intra-
molecular biosensor’ constructs in which 
the protein of interest is fused, via a linker, 
to an effector-domain. Upon activation of 
the biosensor, conformational changes in 
the sensor lead to the induction or loss of 
FRET between fluorophores which can 
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by the elasticity of the fibrillar matrix.18,19 
They also provide a source of growth 
factors and appropriate integrin engage-
ment, resulting in bidirectional signaling 
between the cells and the surrounding 
stromal fibroblasts and ECM (see Fig. 
1).20,21 This approach allowed the three-
dimensional manipulation and fluorescent 
lifetime imaging of RhoA activity during 
invasion to be examined in an interme-
diate-system prior to full in vivo explora-
tion of this biological process. Expansion 
of our initial findings led to the first use 
of FLIM-FRET to monitor molecular 
dynamics of RhoA in live animal tumors 
upon therapeutic intervention. In particu-
lar, dasatinib which shows anti-metastatic 
activity in this pancreatic model, inhibited 
RhoA activity at the poles of mutant p53 
cells in vivo and this effect was indepen-
dent of changes in basal activity within 
the cell body.7,22 Moreover, inhibition of 
this pool of RhoA activity correlated with 
invasion. These results demonstrate that 
RhoA is not only necessary for invasion, 
but suggest that sub-cellular spatial regu-
lation of RhoA activity, as opposed to its 
global activity, may govern invasion effi-
ciency in situ.
Whether this polarized regulation of 
RhoA to the front or rear of cells is driv-
ing protrusion, retraction or both in vivo 
is currently unknown. This, however, 
could be assessed in the future by simul-
taneously imaging cancer cell invasion in 
live animals, in real-time using FLIM-
FRET. Recently, we have performed real-
time FLIM-FRET to examine the spatial 
and temporal regulation of RhoA activity 
on three-dimensional cell derived matrix 
(CDM).18 Similar to our initial observa-
tion in live animals, we cannot only dem-
onstrate the spatial, but now the temporal 
regulation of RhoA during cell movement 
(Fig. 2). The capacity to quantitatively 
assess molecular behavior in live animals 
both temporally and spatially will aid in 
attributing key cellular modes of move-
ment in vivo with signaling events and 
should assist the future development of 
site-specific drug targeting.
Interestingly, in our initial in vitro 
studies we also found that fluorescence 
lifetime imaging could accurately detect 
subtle changes in RhoA activity within 
a large tumor population, as small 
associated with sample instability, small 
incisions in the skin surrounding xeno-
graft tumors are made and a ‘skin flap’ is 
created, allowing images to be acquired at 
a distance from the body of the mouse.5-7 
Using this technique, images can be 
acquired over a short time period and an 
average readout of several parameters can 
be generated using a number of animals. 
Recently this approach has been used in 
combination with multiphoton-based 
FLIM-FRET for deep tissue imaging.8 
Here, the investigators generated a series 
of z-stack sections ranging from 20 to 
100 μm within the tumor tissue and pro-
vided accompanying lifetime maps rep-
resenting the interaction between PKCα 
and the pro-inflammatory chemokine 
receptor CXCR4.8 This analysis, within 
a population of tumor cells, provides a 
representative image of protein-protein 
interplay governed by local environmen-
tal cues from the surface to the interior 
of the tumor. Similarly, FLIM-FRET has 
been used at the single cell level within a 
tumor population to assess chemotherapy-
induced resistance to apoptosis.9
Analysis of RhoA Activity in vivo
Recently, we used FLIM-FRET, for the 
first time, at the sub-cellular level in vivo, 
to examine RhoA activity during cancer 
cell invasion,7 using a genetically defined 
live animal model of pancreatic cancer 
driven by mutations in Kras and p53.10,11 
Since this model replicates human pancre-
atic tumorigenesis in terms of disease pro-
file and metastatic burden12,13 it serves as 
an excellent system to examine the role of 
RhoA which is thought to play a vital role 
in mutant p53-driven invasion.14-17 Here, 
we specifically identified at high resolution 
a small yet important pool of active RhoA 
at the poles of invading cells, not observed 
in vitro, that correlates with invasion in 
vivo.7
Our initial finding that RhoA was 
spatially regulated during invasion was 
achieved using organotypic three-dimen-
sional matrices involving co-culture of 
pancreatic tumor cells with fibrillar col-
lagen I and fibroblasts. Organotypic 
matrices have previously been utilized to 
mimic cell-ECM interactions with regards 
to physical and mechanical forces driven 
be measured within the cell. In this way 
the activation of numerous signal trans-
duction events have been tracked in live 
cells in vitro.1 More recently, changes in 
the fluorescence lifetime of the donor 
fluorophore induced upon FRET have 
been measured using time and frequency 
domain approaches.3 This method is 
insensitive to artifacts caused by differ-
ences or fluctuation in fluorophore levels 
and can therefore provide a more robust 
readout of FRET activity within the given 
specimen.
In vivo FRET Analysis
The employment of fluorescent proteins 
for imaging and tracking cell behav-
ior in vivo has been applied to many 
multi-cellular model organisms includ-
ing Drosophila, Zebrafish and Xenopus 
embryos. These models are better suited 
to intravital imaging than mammalian 
systems due to their transparent nature. 
However, the use of FRET or FLIM for 
in vivo or three-dimensional applications 
has only recently begun to emerge. For 
example, the chemokine-directed motility 
of germ cells during zebrafish embryonic 
development has been investigated using 
FRET.4 Here, the authors demonstrate the 
sub-cellular activation of Rac1 and RhoA 
at the front of migrating cells, where Rac1 
functions to induce actin-rich structures 
while RhoA drives retrograde actin flow. 
Collectively, the formation and retrograde 
movement of these actin-rich structures 
facilitates traction forces between the 
germ cells and the surrounding tissue, via 
E-cadherin, allowing directed cell motil-
ity necessary for embryonic development.4 
This work has implications regarding the 
synchronized and coordinated role of 
RhoGTPases in other fundamental three-
dimensional processes involving both sin-
gle and collective cell movement.
The relative ease of imaging in these 
model systems compared with mamma-
lian models is partly due to the challenges 
of high autofluorescence, light scattering 
and poor tissue penetration found within 
mammalian tissue. Live animal imag-
ing is also inherently demanding due to 
sample instability caused by movement 
of the heart, respiration system and mus-
cle contractions. To overcome problems 
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response, at the single cell level, using 
FLIM-FRET could therefore be used to 
assess the efficiency of cancer drug delivery 
within different zones of the tumor. Akin 
to the vasculature governing drug delivery 
and targeting efficiency, the density and 
topography of the ECM that surrounds 
tumor cells has also recently been shown 
to contribute to the perfusion and access 
of drugs to the tumor tissue.23 Consistent 
with this, we find that not all cells in vivo 
are inactive upon dasatinib treatment.7 As 
tumor cells which are refractory to initial 
the host vasculature compared with cells 
at distal sites (Fig. 3E). The enhanced 
activation of RhoA in invasive mutant 
p53R172H/+ cells proximal to the host vas-
culature (Fig. 3) and at the wound edge,7 
suggests a gradient of activity may exist 
within the local environment of tumors.
In this regard, it is feasible that a simi-
lar scenario could exist regarding drug 
targeting within the tumor environment, 
whereby response to therapeutic inter-
vention may be affected by a similar spa-
tial gradient. The investigation of drug 
subpopulations of mutant p53R172H+/- cells 
proximal to a wound edge showed sig-
nificant RhoA activation while cells at the 
rear of a wound demonstrated a low basal 
activity.7 In line with this, our preliminary 
in vivo findings using quantum dots to 
identify blood vessels show that in non-
invasive p53fl/+ cells there is a low basal 
level of RhoA activity independent of their 
location to the tumor blood supply (Fig. 
3A–D). Invasive mutant p53R172H/+ PDAC 
cells however have significantly higher 
RhoA activity when in close proximity to 
Figure 1. Mutant p53r172H drives PDAC invasion. H&E stained sections of non-invasive p53fl and invasive p53r172H PDAC cells on organotypic matrix. 
Scale bar represent 100 μm.
Figure 2. real-time FLiM-FrET imaging of rhoA activity during motility on 3D-matrix. Mutant p53r172H PDAC on cell derived matrix (CDM) expressing 
the raichu-rhoA reporter with corresponding lifetime map of rhoA activity acquired in real-time. Blue represents the active biosensor and yellow is 
inactive. Scale bar represents 10 μm.
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drug treatment may recolonise or prog-
ress to form micro-metastases, it would be 
beneficial to identify and isolate regions 
of poor drug delivery and response within 
various solid tumor environments using 
FLIM-FRET. We are currently using this 
technique to investigate aspects of the 
tumor environment that may contribute 
to poor drug targeting such as the density 
of ECM component surrounding the cells, 
their proximity to host vasculature or their 
orientation with regards to tumor cell cor-
tex or border. This work could assist in 
the design, scheduling and stratification 
of future combination therapy to sensitize 
the tumor for efficient drug delivery.
Applications of FLIM or FRET  
for Drug Discovery
Using FLIM-FRET alone or multi-
plexed with additional functional report-
ers, the groups of French and Bastiaens 
have adapted Time domain or frequency 
domain based-FLIM, respectively, to 
allow for fast FLIM in a 96-well high-
throughput format suitable for screening 
drug response or molecular profiling, such 
as the in situ identification of tyrosine 
phosphorylation networks in response to 
EGFR signaling.24,25 Adaptation of this 
type of high throughput FLIM-FRET 
imaging for three-dimensional settings 
may provide further context-dependent 
detail regarding drug response not feasible 
in vitro. In line with this, French and col-
leagues have also extended the application 
of lifetime imaging from cell based disease 
models to compare the intrinsic lifetime 
Figure 3. Spatial regulation of rhoA activity 
within tumor population. (A) representa-
tive image of cells (green) proximal to host 
vasculature (red). (B) p53fl PDAC cells distal to 
host vasculature expressing the raichu-rhoA 
reporter (green) with corresponding in vivo 
lifetime map of rhoA activity, respectively. (C) 
p53fl PDAC cells expressing the raichu-rhoA 
reporter (green) proximal to host vasculature 
(red) with corresponding in vivo lifetime 
map of rhoA activity, respectively. (D and E) 
Quantification of lifetime measurements of 
rhoA activity within the tumor environment. 
Lifetime pseudo-colors; blue represents ac-
tive biosensor and yellow represents inactive 
biosensor. Figure partially reproduced from 
original Cancer res article in reference 7. 
Scale bar, 30 μm. Columns, mean; bars, SE. 
**p < 0.01.
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contextual detail this affords, highlight 
the need to advance FLIM-FRET imaging 
in the future by adapting FRET biosen-
sors to incorporating the use of red-and far 
red FRET pairs. In this way, the reduced 
light scattering, autofluorescence and 
absorption by tissue found at longer wave-
lengths should provide a powerful tool for 
directly observing fundamental events at 
even greater depth in intact native tissue 
than can currently be achieved using the 
fluorescent lifetime of low wavelength 
biosensors such as the GFP-RFP based 
Raichu-RhoA probe reported here in ref-
erence 7.
Future Perspective
Our findings demonstrate the potential 
utility of FLIM-FRET in the analysis of 
dynamic biomarkers during the assess-
ment of various therapeutic drug regimes. 
Such detailed analysis in vivo enables the 
detection and precise quantification of 
subtle changes in protein activity follow-
ing therapeutic intervention that cannot 
always be detected in vitro. In this regard, 
the future application of complex three-
dimensional in vitro and in vivo systems, 
which are amenable to molecular manipu-
lation may improve our understanding of 
cell behavior in a more physiological and 
functional setting and therefore partially 
reduce the current attrition rate of new 
compounds entering clinical trials due 
to lack of appropriate initial experimen-
tal model systems in which to test drug 
efficacy.36
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